A new audit finds that the family directed $10.7 billion from the drugmaker to family-controlled trusts and holding companies, as legal pressure tightened around Purdue.As scrutiny of Purdue Pharmaâ€™s role in the opioid epidemic intensified during the past dozen years, its owners, members of the Sackler family, withdrew more than $10 billion from the company, distributing it among trusts and overseas holding companies, according to a new audit commissioned by Purdue.A new audit finds that the family directed $10.7 billion from the drugmaker to family-controlled trusts and holding companies, as legal pressure tightened around Purdue.